- SPANNR
- Posts
- Issue #44
Issue #44
Issue #44
March 30, 2023 | Issue #44
Good evening. Welcome back to another issue of Spannr.In this week's newsletter:š Who will win the race to treat dementia? šļø MHRA's clinical trial overhaulš Good reads from around the web
Doctors, Drug Dealers, or AI: Who Will Win the Race to Treat Dementia?
Imagine watching a loved one slowly lose their memory, their identity slipping away as they struggle to hold onto the simplest of tasks.This was the reality facing Adam Tapp and his family when his father was diagnosed with Alzheimer's.His once vibrant and active father was now unable to hold a conversation, play guitar, or even function on his own. It was a heartbreaking experience that many families face when dealing with neurodegenerative diseases.Determined to find a solution, Adam took a deep dive into the world of cognitive science and psychiatry, seeking out potential treatments that could help his father and others suffering from similar conditions.It was during this time that he stumbled upon an unlikely candidate - psychedelics.In our latest article, we explore the exciting new research into the potential of psychedelics as a treatment for age-related diseases such as Alzheimer's.
Longevity Venture Partners, a Baltimore-based fund focused on investing in companies that develop technologies and solutions to support the aging population, has announced the closing of its $30 million fund
The Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom's FDA equivalent, has announced plans to streamline the process for clinical trial approvals, in what is being described as the biggest overhaul of trial regulation in 20 years.The aim is to make the process quicker and more efficient, reducing the time it takes for new treatments to reach patients. The changes include:
Simplifying the application process
Introducing more flexible and proportionate regulations
Clinical trials are an essential part of the drug development process ā as most of you already know ā and a more streamlined and efficient approval process could help speed up the translation of promising age-related research into clinical practice.Here's the link to learn more. Otherwise, continue scrolling to see what else was trending this week in the world of longevity šš.
Retinal scans: A non-invasive, inexpensive method to track human aging (Buck Institute)
Microplastics are messing with the microbiomes of seabirds (MIT Technology Review)
Why Do So Few Biotech Startups Want To Be The Next Big Pharma Company? (Crunchbase)
'Live free and die?' The sad state of U.S. life expectancy (NPR)
Think Getting Into College Is Hard? Try Applying for These Gyms (NYT)
Believe it or not, we have an underpopulation problem to solve ā and thereās good reason to believe aging isnāt inevitable (Boston Globe)
The Age-Defying, Happiness-Generating Power of True Friendships (Men's Health)
The healthspan revolution: how to live a long, strong and happy life (The Guardian)
Welcome to the anti-aging era: How reversing your 'biological age' has become healthcare's hottest trend (Insider)
A new paper explores what āsupercentenariansā have in common. Turns out itās bad record-keeping (Vox)
We're nowhere near reaching the maximum human life span, controversial study suggests (Live Science)
Performance:
Latest Price: $96.367d-Return: -7.97%Market Cap: $9.87b
ABOUT SPANNR
We are dedicated to helping people understand the biggest business and health story of all time: the unprecedented transformation of society that will result from extending human healthspan and lifespan.
If you have any questions about Spannr or want to get to know us better,
ā we'd love to hear from you. We appreciate your interest in what we are creating.